Skip to main content

Table 4 One-year clinical outcomes

From: Intra-coronary morphine versus placebo in the treatment of acute ST-segment elevation myocardial infarction: the MIAMI randomized controlled trial

  Morphine group
(n = 45)
Placebo group
(n = 43)
P value
Major adverse cardiac events, n (%) 7 (15.6) 8 (18.6) 0.70
 Cardiovascular death 0 (0.0) 1 (2.3)  
 Heart failure 2 (4.4) 2 (4.6)  
 STEMI 1 (2.2) 1 (2.3)  
 Stable angina 3 (6.7) 3 (7.0)  
 Sustained ventricular arrhythmia 1 (2.2) 1 (2.3)  
Other clinical events, n (%) 5 (11.1) 4 (9.3) 0.78
 Non-cardiovascular death 1 (2.2) 0 (0.0)  
 CABG 1 (2.2) 2 (4.6)  
 Elective PCI 3 (6.7) 2 (4.6)  
  1. CABG coronary artery bypass grafting, PCI percutaneous coronary intervention, STEMI ST-elevation myocardial infarction